Drug-resistant and immune-escape HBV mutants in HIV-infected hosts. - Archive ouverte HAL Access content directly
Journal Articles Antiviral Therapy Year : 2010

Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.

(1, 2) , (1) , (2) , (3) , (1, 2) , (3, 4)


HIV-HBV-coinfected patients require optimal control of viral replication in order to prevent the development of severe comorbidities, such as liver cirrhosis and hepatocellular carcinoma. The genetic diversity of HBV is a poorly investigated factor of such viral replication in HIV-infected hosts. HBV genome diversity can be differentiated into two major aspects: genotypic and phenotypic. Genotypic diversity is more related to the natural history of HBV infection and genotypes are mostly determined by geographical origin of the hosts. Phenotypic diversity arises from attempts to escape from host immune surveillance (that is, precore, core and basal core promoter mutants), selection resulting from the use of treatments with weak genetic barrier (that is, pol mutants), exposure to hepatitis B immunoglobulin (that is, 'immune-escape' S gene mutants) or treatment-induced mutations from overlapping genes (that is, pol mutants inducing 'vaccine-escape' S gene mutants). pol mutations typically lead to uncontrolled viral replication, whereas S gene mutations can significantly alter hepatitis B surface antigen synthesis and reduce binding to antibodies, which renders individuals who are vaccinated or cured of HBV infection susceptible to infection. For patients coinfected with HIV, hepatitis B treatment options that aim to reduce the risk of HBV mutations from emerging must be seriously considered, not only from clinical but also public health perspectives.
Fichier principal
Vignette du fichier
AVT-09-RV-1412-R1-LACOMBE.pdf (113.75 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-00491989 , version 1 (14-06-2010)



Karine Lacombe, Anders Boyd, Joël Gozlan, Fabien Lavocat, Pierre-Marie Girard, et al.. Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.. Antiviral Therapy, 2010, 15 (3 Pt B), pp.493-7. ⟨10.3851/IMP1495⟩. ⟨inserm-00491989⟩
312 View
572 Download



Gmail Facebook Twitter LinkedIn More